Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yahui Zhu, Jing Zhou, Lijing Zhu, Wenjing Hu, Baorui Liu & Li Xie. (2022) Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer. Human Vaccines & Immunotherapeutics 18:5.
Read now
Read now
Alfonso Duenas-Gonzalez & Aurora Gonzalez-Fierro. (2019) Pharmacodynamics of current and emerging treatments for cervical cancer. Expert Opinion on Drug Metabolism & Toxicology 15:8, pages 671-682.
Read now
Read now
Articles from other publishers (43)
Majd Al Assaad, Houssein Safa, Chiara Mercinelli, Philippe E. Spiess, Andrea Necchi & Jad Chahoud. (2024) Immune-based Therapies for Penile Cancer. Urologic Clinics of North America.
Crossref
Crossref
Rosario García-Rocha, Alberto Monroy-García, Ana Luisa Vázquez-Cruz, Luis Antonio Marín-Aquino, Benny Weiss-Steider, Jorge Hernández-Montes, Christian Azucena Don-López, Gabriela Molina-Castillo & María de Lourdes Mora-García. (2024) Adenosine Increases the Immunosuppressive Capacity of Cervical Cancer Cells by Increasing PD-L1 Expression and TGF-β Production through Its Interaction with A2AR/A2BR. Pharmaceuticals 17:3, pages 397.
Crossref
Crossref
Siyue Jiang, Wenhua Wang & Yongxiu Yang. (2024) TIGIT: A potential immunotherapy target for gynecological cancers. Pathology - Research and Practice 255, pages 155202.
Crossref
Crossref
G. Anju, Meenakshi Rao, Poonam Abhay Elhence, Aasma Nalwa, Pratibha Singh, Garima Yadav, Akhil Dhanesh Goel & Devisowmiya Thiruvengadam. (2024) Expression of Programmed Death Ligand 1 [PD-L1] and Mismatch Repair Status in Squamous Cell Carcinomas of Cervix. The Journal of Obstetrics and Gynecology of India.
Crossref
Crossref
Fan Guo, Ruijiao Lu, Weina Kong, Miyessar Anwar & Yangchun Feng. (2024) DNA mismatch repair system regulates the expression of PD-L1 through DNMTs in cervical cancer. Cancer Cell International 24:1.
Crossref
Crossref
Hanlin Fu, Zhihui Fu, Meng Mao, Lulu Si, Jing Bai, Qian Wang & Ruixia Guo. (2023) Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 189, pages 104084.
Crossref
Crossref
Daniel Margul, Camilla Yu & Mariam M. AlHilli. (2023) Tumor Immune Microenvironment in Gynecologic Cancers. Cancers 15:15, pages 3849.
Crossref
Crossref
YingGang Zou, Ying Xu, XiaoChen Chen & Lianwen Zheng. (2023) Advances in the application of immune checkpoint inhibitors in gynecological tumors. International Immunopharmacology 117, pages 109774.
Crossref
Crossref
Xiang-Cheng Hu, Chen-Xiao Gan, Hui-Min Zheng, Xue-Ping Wu & Wen-Sheng Pan. (2023) Immunotherapy in combination with chemotherapy for Peutz-Jeghers syndrome with advanced cervical cancer: A case report. World Journal of Gastrointestinal Surgery 15:3, pages 480-487.
Crossref
Crossref
E.M. Oliushina, L.E. Zavalishina, Yu.Yu. Andreeva, O.A. Kuznetsova, L.V. Moskvina & G.A. Frank. (2023) Predictive markers of immunotherapy in cervical cancer. Arkhiv patologii 85:5, pages 5.
Crossref
Crossref
Yang Li, Fangrong Shen, Qingqing Tan, Youguo Chen & Yanzheng Gu. (2023) Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer. Technology in Cancer Research & Treatment 22.
Crossref
Crossref
Irene A. George, Richa Chauhan, R.E. Dhawale, Roshini Iyer, Sewanti Limaye, R. Sankaranarayanan, R. Venkataramanan & Prashant Kumar. (2022) Insights into therapy resistance in cervical cancer. Advances in Cancer Biology - Metastasis 6, pages 100074.
Crossref
Crossref
Xiaoying Sun, Lili Liu, Ting Wan, Qidan Huang, Jieping Chen, Rongzhen Luo & Jihong Liu. (2022) The prognostic impact of the immune microenvironment in small-cell neuroendocrine carcinoma of the uterine cervix: PD-L1 and immune cell subtypes. Cancer Cell International 22:1.
Crossref
Crossref
Yunkai Xie, Weimin Kong, Xiaoling Zhao, He Zhang, Dan Luo & Shuning Chen. (2022) Immune checkpoint inhibitors in cervical cancer: Current status and research progress. Frontiers in Oncology 12.
Crossref
Crossref
Weijia Huang, Jiewei Liu, Kai Xu, Huilin Chen & Ce Bian. (2022) PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed. Frontiers in Oncology 12.
Crossref
Crossref
Rina Doukuni, Takuro Kobori, Chihiro Tanaka, Mayuka Tameishi, Yoko Urashima, Takuya Ito & Tokio Obata. (2022) Moesin Serves as Scaffold Protein for PD-L1 in Human Uterine Cervical Squamous Carcinoma Cells. Journal of Clinical Medicine 11:13, pages 3830.
Crossref
Crossref
Hanqun Zhang, Shisheng Tan, Chunju Fang, Qi Zhang, Xue Cao & Yuncong Liu. (2022) PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer. Frontiers in Oncology 12.
Crossref
Crossref
宇 孟. (2022) New Progress in Drug Treatment of Recurrent and Metastatic Cervical Cancer. Medical Diagnosis 12:01, pages 1-6.
Crossref
Crossref
A. V. Tarasova, K. A. Ganina, M. A. Meshkova, Yu. V. Solovyeva, E. E. Ivanova & L. N. Akimov. (2021) Modern possibilities of using immunotherapy in the treatment of cervical cancer. Tumors of female reproductive system 17:2, pages 104-111.
Crossref
Crossref
Ying Tang, Anne X.J. Zhang, Guangyu Chen, Yanheng Wu & Wenyi Gu. (2021) Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives. Molecular Therapy - Oncolytics 22, pages 410-430.
Crossref
Crossref
A. A. Rumyantsev & A. Yu. Anokhin. (2021) The role of immunotherapy in the management of metastatic/recurrent female reproductive system neoplasms. Meditsinskiy sovet = Medical Council:9, pages 76-86.
Crossref
Crossref
Minjuan Xu, Jun Huang & Liefeng Wang. (2021) Effects of Liposomal Nanoparticles-Mediated miR-126 on Cervical Cancer Cells via Anti-Programmed Cell Death-1/Programmed Death Ligand 1 (PD-1/PD-L1) Signaling. Science of Advanced Materials 13:8, pages 1506-1511.
Crossref
Crossref
Rachelle P. Mendoza, Tahmineh Haidary, Elmer Gabutan, Ying Yin Zhou, Zaheer Bukhari, Courtney Connelly, Wen-Ching Lee, Yi-Chun Lee, Raj Wadgaonkar, Raag Agrawal, M. A. Haseeb & Raavi Gupta. (2021) Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer. Scientific Reports 11:1.
Crossref
Crossref
Xiaoyu Ji, Lei Sui, Kejuan Song, Teng Lv, Han Zhao & Qin Yao. (2021) PD‐L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer. Cancer Medicine 10:14, pages 4743-4751.
Crossref
Crossref
Tianyu Zhang, Shuangshuang Zheng, Yang Liu, Xiao Li, Jing Wu, Yue Sun & Guoyan Liu. (2021) DNA damage response and PD-1/PD-L1 pathway in ovarian cancer. DNA Repair 102, pages 103112.
Crossref
Crossref
Lucie Mouková. (2021) New Treatment Options for Cervical Cancer. Onkologie 15:3, pages 119-122.
Crossref
Crossref
Lifang Zhang, Yu Zhao, Quanmei Tu, Xiangyang Xue, Xueqiong Zhu & Kong-Nan Zhao. (2021) The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy. Current Medicinal Chemistry 28:5, pages 893-909.
Crossref
Crossref
Yuexun Xu, Hui Luo, Qunchao Hu & Haiyan Zhu. (2021) Identification of Potential Driver Genes Based on Multi-Genomic Data in Cervical Cancer. Frontiers in Genetics 12.
Crossref
Crossref
Lennox Chitsike & Penelope Duerksen-Hughes. (2020) The Potential of Immune Checkpoint Blockade in Cervical Cancer: Can Combinatorial Regimens Maximize Response? A Review of the Literature. Current Treatment Options in Oncology 21:12.
Crossref
Crossref
Laura Attademo, Valentina Tuninetti, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Rosa Tambaro, Giorgio Valabrega, Lucia Musacchio, Sergio Venanzio Setola, Patrizia Piccirillo, Daniela Califano, Anna Spina, Simona Losito, Stefano Greggi & Sandro Pignata. (2020) Immunotherapy in cervix cancer. Cancer Treatment Reviews 90, pages 102088.
Crossref
Crossref
Matthew Ryan Carroll, Preetha Ramalingam, Gloria Salvo, Junya Fujimoto, Luisa Maren Solis Soto, Natacha Phoolcharoen, Robert Tyler Hillman, Robert Cardnell, Lauren Byers & Michael Frumovitz. (2020) Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. International Journal of Gynecologic Cancer 30:9, pages 1303-1307.
Crossref
Crossref
A. А. Rumyantsev. (2020) Molecular-guided therapy for disseminated cervical cancer: present and future. Meditsinskiy sovet = Medical Council:9, pages 121-126.
Crossref
Crossref
Soumaya Allouch, Ahmed Malki, Asma Allouch, Ishita Gupta, Semir Vranic & Ala-Eddin Al Moustafa. (2020) High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions. Frontiers in Oncology 10.
Crossref
Crossref
Masahiro Kagabu, Takayuki Nagasawa, Chie Sato, Yasuko Fukagawa, Hanae Kawamura, Hidetoshi Tomabechi, Shuji Takemoto, Tadahiro Shoji & Tsukasa Baba. (2020) Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions. International Journal of Molecular Sciences 21:7, pages 2335.
Crossref
Crossref
Miguel A. Berenguer Frances, Isabel Linares-Galiana, Rut Cañas Cortés, Susanna Marín i Borrás, Cristina Gutiérrez Miguélez, Dina Najjari, Andrea Slocker, Cinta Bellobí, María Santacana, María Pané Foix, M. Henar Alonso, Arturo Navarro-Martin, Silvia Comas Antón & Ferran Guedea. (2020) Changes of CD68, CD163, and PD-L1 tumor expression during high-dose-rate and pulsed-dose-rate brachytherapy for cervical cancer. Brachytherapy 19:1, pages 51-59.
Crossref
Crossref
Masafumi Koshiyama, Miwa Nakagawa & Ayumi Ono. (2019) The Preventive Effect of Dietary Antioxidants against Cervical Cancer versus the Promotive Effect of Tobacco Smoking. Healthcare 7:4, pages 162.
Crossref
Crossref
Hui Li, Jinglin Zhang, Joanna Hung Man Tong, Anthony Wing Hung Chan, Jun Yu, Wei Kang & Ka Fai To. (2019) Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors. International Journal of Molecular Sciences 20:23, pages 5999.
Crossref
Crossref
Masahiro Kagabu, Takayuki Nagasawa, Daisuke Fukagawa, Hidetoshi Tomabechi, Saiya Sato, Tadahiro Shoji & Tsukasa Baba. (2019) Immunotherapy for Uterine Cervical Cancer. Healthcare 7:3, pages 108.
Crossref
Crossref
Christian M. Domröse & Peter Mallmann. (2019) Innovative Therapien beim metastasierten ZervixkarzinomInnovative treatments for metastasized cervical cancer. Der Gynäkologe 52:8, pages 601-604.
Crossref
Crossref
Sarah Morgan, Elzbieta Slodkowska, Carlos Parra‐Herran & Jelena Mirkovic. (2019)
PD
‐L1,
RB
1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type, of the uterine cervix
. Histopathology 74:7, pages 997-1004.
Crossref
Crossref
Kun Jiang, Brian Martens, Logan Meyer, Kim Truong & Gregory Y. Lauwers. (2019) A mismatch repair-deficient and HPV-negative anorectal squamous cell carcinoma. Virchows Archiv 474:6, pages 769-773.
Crossref
Crossref
Yuncong Liu, Li Wu, Ruizhan Tong, Feiyue Yang, Limei Yin, Mengqian Li, Liting You, Jianxin Xue & You Lu. (2019) PD-1/PD-L1 Inhibitors in Cervical Cancer. Frontiers in Pharmacology 10.
Crossref
Crossref
Juliane Lippert, Silke Appenzeller, Raimunde Liang, Silviu Sbiera, Stefan Kircher, Barbara Altieri, Indrajit Nanda, Isabel Weigand, Andrea Gehrig, Sonja Steinhauer, Renzo J M Riemens, Andreas Rosenwald, Clemens R Müller, Matthias Kroiss, Simone Rost, Martin Fassnacht & Cristina L Ronchi. (2018) Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. The Journal of Clinical Endocrinology & Metabolism 103:12, pages 4511-4523.
Crossref
Crossref